OTCMKTS:LOGC LogicBio Therapeutics Q1 2026 Earnings Report $8.60 -0.55 (-6.01%) As of 03:59 PM Eastern Profile LogicBio Therapeutics EPS ResultsActual EPSN/AConsensus EPS -$0.04Beat/MissN/AOne Year Ago EPSN/ALogicBio Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$32.40 millionBeat/MissN/AYoY Revenue GrowthN/ALogicBio Therapeutics Announcement DetailsQuarterQ1 2026Date5/15/2026TimeN/AConference Call DateFriday, May 15, 2026Conference Call Time8:00AM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Company ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) LogicBio Therapeutics Earnings HeadlinesContextLogic Holdings Inc. Announces Scott Stewart as Chief Financial Officer & Chief Operating OfficerJune 1, 2026 | globenewswire.comContextLogic Holdings Inc. Publishes Q&A Following First Quarter 2026 ResultsMay 22, 2026 | globenewswire.comBuy the “unseen winner of the AI race” before July 22Marc Chaikin - the analyst who called Nvidia before a 45,000% surge - says one overlooked AI stock could split into three separate companies in a rare event called a 'starburst' before July 22. Investors who buy shares before the announcement could automatically receive equal shares in each spinoff. A similar starburst at GE unlocked $184 billion for shareholders across three new companies.June 24 at 1:00 AM | Chaikin Analytics (Ad)ContextLogic Holdings Inc. Reports First-Quarter 2026 Financial ResultsMay 15, 2026 | globenewswire.comContextLogic Appoints Paul S. Levy to Board of DirectorsApril 1, 2026 | globenewswire.comContextLogic Holdings Inc. Reports Fourth-Quarter and Fiscal Year 2025 Financial ResultsMarch 5, 2026 | globenewswire.comSee More LogicBio Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like LogicBio Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on LogicBio Therapeutics and other key companies, straight to your email. Email Address About LogicBio TherapeuticsLogicBio Therapeutics (OTCMKTS:LOGC), a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.View LogicBio Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Why KB Home Could Reward Patient Investors LaterWhy nVent Could Be a Long-Term AI Infrastructure WinnerChevron’s Microsoft Deal Turns Natural Gas Into an AI TradeMicron’s Sudden Plunge May Be an AI Buying ChanceMarathon Petroleum Is Back, But Cycles Still MatterLiquid Gold: The AI Cooling Retrofit TradeCopa Holdings May Be the Airline Stock Built to Break Out Upcoming Earnings NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026)Citigroup (7/14/2026)ASML (7/15/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
